• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 • 上一篇    下一篇

拉莫三嗪治疗脑血管病后继发癫痫的疗效及安全性分析

张晓平   

  1. 汝州市人民医院
  • 收稿日期:2018-12-26 修回日期:2019-03-29 出版日期:2019-04-25 发布日期:2019-04-25

Efficacy and Safety of Lamotrigine in the Treatment of Epilepsy Secondary to Cerebrovascular Disease

zhangxiaoping   

  1. Ruzhou People''s Hospital
  • Received:2018-12-26 Revised:2019-03-29 Online:2019-04-25 Published:2019-04-25

摘要: 目的:探讨拉莫三嗪治疗脑血管病后继发癫痫的疗效及安全性。方法:将2016年4月至2018年4月期间在本院接受治疗的脑血管病后继发癫痫患者60例作为研究资料,随机分2组,每组各30例。对照组为卡马西平片治疗,观察组为拉莫三嗪片治疗,评价两组治疗效果及不良反应发生情况。结果:观察组治疗总有效率为96.67%,与对照组比较明显更高,P<0.05;观察组不良反应率6.67%显著低于对照组30.00%,P<0.05。结论:对于脑血管病后继发癫痫患者给予拉莫三嗪片作为主要药物进行治疗,可有效促使癫痫发作次数降低或消失,且不良反应较少,可为临床用药提供参考。

Abstract: Objective: To investigate the clinical effect and safety of lamotrigine in the treatment of epilepsy secondary to cerebrovascular disease. Methods:60 patients with epilepsy secondary to cerebrovascular disease treated in our hospital from April 2016 to April 2018 were divided into 30 cases according to the treatment plan.the control group was treated with carbamazepine tablets,and the observation group was treated with lamotrigine tablets. The therapeutic effect and adverse reactions of the two groups were evaluated. Results: The total effective rate of the observation group was 96.67%,which was significantly higher than that of the control group, P<0.05; the adverse reaction rate of the observation group was 6.67%,which was significantly lower than that of the control group was 30.00%,P<0.05. Conclusion:For patients with epilepsy secondary to cerebrovascular disease, lamotrigine tablets were given as the main drug for treatment,and promote patients to return to normal life. The drug has high safety and fewer adverse reactions,which is worthy of popularization and application.